CurrentAetnaPolicy 0215

Lyme Disease and other Tick-Borne Diseases

This Aetna clinical policy bulletin governs medical necessity and coverage for intravenous antibiotic therapy, diagnostic testing, and other treatments related to Lyme disease and selected tick-borne diseases for insured members.

Policy Summary

PayerAetna

PolicyLyme Disease and other Tick-Borne Diseases

Policy CodePolicy 0215

Change TypeNo material change

Effective DateMar 17, 1998

Next Review DateFeb 22, 2024

Key ActionObtain objective clinical signs and validated serology/CSF testing before authorizing outpatient IV antibiotic therapy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4-weekinitial outpatient IV course

one repeatallowed repeat course

≥26experimental tests

2 g/dayceftriaxone dose

2–3 weeksneuroborreliosis duration

03/17/1998

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Lyme Disease and Selected Tick‑Borne Diseases

Initial Therapy

Covered when ALL of the following are met

Initial IV therapy general requirements: Diagnosis of Lyme disease based on clinical presentation of signs and symptoms compatible with disease AND supported by positive serologic and/or CSF titer by IFA, Prevue Borrelia burgdorferi antibody detection assay, or ELISA validated by a positive Western Blot per CDC criteria.

CDC two-test approach; see Western blot band criteria in policy

Indications for initial IV therapy (one required): One of the following must be present: 1) Lyme arthritis that persists after failing a 4-week course of appropriate oral antibiotic therapy; 2) Moderate-to-severe cardiac involvement as evidenced by any of: first-degree heart block with PR interval >0.4 seconds, congestive heart failure, myopericarditis, second- or higher-degree AV block; 3) Neurologic involvement (neuroborreliosis) evidenced by encephalopathy/encephalomyelitis, meningitis confirmed by CSF lymphocytic pleocytosis with evidence of antibody production against Borrelia in CSF, or sensory/motor radiculoneuropathy or peripheral neuropathy; 4) Any pregnant woman with stage II early dissemination with organ-specific manifestations (arthritic, cardiac, or neurologic); 5) Stage III late Lyme disease with arthritis and/or neurologic complications such as encephalomyelitis/subacute encephalitis.

Each listed organ-specific manifestation qualifies

Repeat Therapy

Covered when ALL of the following are met

Repeat IV therapy criteria: 1) Member met criteria for initial IV antibiotic therapy with lab results obtained within the past 3 months; AND 2) Member completed an initial course of appropriate IV antibiotic therapy; AND 3) Member has objective evidence of either relapse of infection, progression of Lyme disease organ damage, and/or a new focus or type of organ damage.Lab results within 3 months

Allows one repeat 4-week course

Experimental / Investigational / Not Medically Necessary

Experimental/Investigational therapies and diagnostics (not covered): Initial IV antibiotic therapy for early Lyme disease or new-onset Lyme arthritis; IV therapy for flu-like syndromes or nonspecific chronic symptoms (e.g., chronic fatigue, difficulty concentrating, musculoskeletal pain); prophylaxis for asymptomatic persons with only positive immunologic tests; mild cardiac involvement; isolated neurologic manifestations such as Bell's palsy; localized erythema migrans in pregnancy; additional antibiotic therapy for post-treatment persistently fatigued patients; and the following diagnostic tests and procedures: antigen detection, Borrelia culture, C6 peptide ELISA, CD57+ counts, CXCL13, complement split products, cytokine analysis, immune complexes, iSpot/ELISPOT, lymphocyte markers, lymphocyte transformation test, measurement of NK cells, PCR for identification or quantification, PET/SPECT imaging, provocative testing, serum borreliacidal assay, urine antigen assays (e.g., Nanotrap OspA), xenodiagnosis, and other listed investigational methods are considered experimental/investigational and not medically necessary.

Policy lists many specific tests and therapies considered experimental/investigational

Initial/Standard therapy coverage

Covered when ALL of the following are met (per evidence/guideline statements in document):

Appropriate indication: Objective clinical signs of Lyme disease or neuroborreliosis (e.g., erythema migrans, neurologic late manifestation, pauciarticular arthritis, or CSF‑confirmed neuroborreliosis).

Supported by guideline statements

Laboratory confirmation correlated with timing: Serologic testing using the CDC two-step approach (ELISA or IFA followed by Western blot) or demonstration of intrathecal Borrelia antibody production in CSF must be interpreted in the context of symptom duration; serology alone without clinical correlation is insufficient.

CDC and guideline guidance

Standard course of therapy used first: Use guideline-recommended antibiotic regimens and durations (e.g., oral doxycycline for erythema migrans or peripheral nervous system disease; IV ceftriaxone 2 g daily for CNS manifestations), with typical neuroborreliosis durations of 2–3 weeks and EFNS recommendation of 14 days for acute LNB peripheral disease and 3 weeks for late LNB when appropriate.

Supported by AAN/EFNS and UpToDate summaries

Unproven / Not medically necessary indications

Not covered / not supported when ANY of the following are present:

Prolonged or repeated antibiotics for PLDS/chronic LD: Repeated or prolonged antibiotic courses for patients with persistent non‑specific symptoms after standard treatment (post‑Lyme syndrome or 'chronic Lyme disease') are not supported by randomized controlled trials and are associated with adverse events; therefore prolonged therapy is not indicated.

Randomized trials show no sustained benefit

Treatment based solely on seropositivity or nonspecific symptoms: Antibiotic therapy based only on persistent seropositivity, isolated positive antibody tests without compatible clinical findings, or nonspecific symptoms (fatigue, arthralgia) is not justified.

Seropositivity without symptoms does not justify antibiotics

Treatment recommendations for Lyme neuroborreliosis and Lyme arthritis

Covered when criteria below are met:

Acute Lyme neuroborreliosis (LNB, symptom duration <6 months): Offer a single 14-day course of antibiotics; oral doxycycline 200 mg daily and IV ceftriaxone 2 g daily are equally effective for peripheral nervous system disease (including meningitis and radiculoneuritis).symptom duration <6 months

Children treated as adults except doxycycline contraindicated under age 8

CNS manifestations of LNB: Treat with IV ceftriaxone 2 g daily for 14 days.CNS involvement

Late LNB (symptom duration >6 months): Treat with IV ceftriaxone 2 g daily for 3 weeks.symptom duration >6 months

Therapy modality and prolonged IV therapy evidence

Covered when specific clinical indications are met (per guideline summaries and trials):

IV therapy for severe cardiac manifestations: Indications for hospitalization and initial IV antibiotic therapy include symptomatic patients (e.g., syncope, dyspnea, chest pain), second- or third-degree AV block, or first-degree AV block with markedly prolonged PR interval (>= 300 milliseconds); continue IV therapy until high-grade AV block resolves and PR <300 ms, then switch to oral to complete a 21–28 day course.PR >= 300 ms

UpToDate and guideline summaries

Oral therapy preferred when appropriate: Under most circumstances, oral therapy is effective and preferred over IV due to equivalent efficacies, tolerability, and cost; IV therapy reserved for hospitalized patients, severe neurologic involvement, or failure of oral regimens.

IDSA/AAN/ACR guideline draft and UpToDate

Evidence regarding prolonged IV antibiotics for persistent symptoms: Randomized trials of prolonged IV ceftriaxone (2 g daily for 30 days) followed by oral doxycycline (200 mg daily for 60 days) did not show benefit over placebo for persistent symptoms; prolonged IV retreatment is controversial and associated with serious adverse events in some reports.

Diagnostics: serology, biomarkers, and investigational urine OspA

Diagnostic confirmation and investigational diagnostics:

Serology and PCR: Positive ELISA for IgG should be followed by IgG immunoblot (CDC two-step); positive PCR from synovial fluid adds diagnostic certainty for Lyme arthritis. Serum antibody positivity without typical symptoms does not justify antibiotic treatment.

Gaubitz; diagnostic guidance

Biomarker research: Biomarkers (various cytokines, chemokines, immune cell markers, and miRNAs) have been reported as modulated in antibiotic-refractory Lyme arthritis, but evidence is limited and requires well-powered studies; panels may be promising pending further validation.

Systematic review identified 26 studies

Urinary OspA testing (investigational): Urinary OspA C-terminal peptide detection using Nanotrap concentration and a specific monoclonal antibody has been evaluated (Magni et al 2015) on hundreds of urine samples to improve early-stage diagnostic specificity, but this remains investigational and is not established as a diagnostic standard.

Magni et al study

Testing ticks for Borrelia burgdorferi or other organisms is considered experimental/investigational and is not a medically useful sole basis for deciding treatment. Encounters coded for screening based on testing ticks (e.g., ICD-10 Z11.2, Z11.8) are identified in the policy as not indicated; scheduled repeated testing of ticks or repeat testing without a change in the member's signs or symptoms is not medically necessary.

Polymerase chain reaction (PCR) testing for B. burgdorferi DNA or RNA has not been validated for routine diagnosis or for monitoring response to therapy and remains a research technique. PCR may be corroborative only in limited contexts (for example, symptom duration <6 weeks when antibodies may be absent), but routine clinical use is not recommended due to concerns about contamination, limited clinical-series data, and lack of standardization.

Single photon emission computed tomographic (SPECT) brain scans are unreliable for diagnosing nervous system Lyme disease: qualitative SPECT is highly variable, shows no pattern specific to Lyme disease, and has no established positive or negative predictive value. Therefore SPECT (and similar perfusion imaging used qualitatively) is not recommended as a diagnostic test for nervous system Lyme disease.

There is no high-quality evidence to support long-term combined antibiotic regimens or other unproven therapies (for example, combined prolonged antibiotics or Antibiotic Augmented Thermo‑Eradication) as established treatments for Lyme arthritis or chronic/post‑treatment Lyme presentations. Reports of patient-reported benefit exist for some novel approaches, but these are uncontrolled and insufficient to support routine use; combined or prolonged regimens are therefore considered unsupported by the evidence.

Contemporary guideline summaries and reviews do not recommend intramuscular penicillin or routine long-term combined antibiotic treatments as preferred therapeutic options. Intramuscular antibiotics are not described as standard therapy in current guideline sources, and long-term combined antibiotic approaches lack reproducible evidence of benefit and are not recommended for routine clinical use.

The CDC and guideline panels advise against certain laboratory methods for clinical use because they lack independent, reproducible validation. Examples include urine antigen capture assays, DNA testing modalities not standardized for routine use, lymphocyte transformation tests, and quantitative CD57 lymphocyte assays; these methods should be avoided in routine clinical practice pending further validation.

This Clinical Policy Bulletin provides a partial, general description of plan or program benefits and is not a contract. Coverage determinations remain subject to the member’s plan terms; the bulletin is intended to assist in administering plan benefits but does not guarantee coverage or constitute medical advice.

Long-term intravenous antibiotic therapy is generally not medically necessary for immunocompetent persons with Bartonella-associated vasculo-proliferative disease or Bartonella bacteremia (except in endocarditis or severe systemic infection), and IV therapy for Q fever is considered experimental. These indications are not supported for routine prolonged IV therapy.

Prolonged, repeated, or chronic parenteral antibiotic therapy for 'chronic Lyme disease' or for persistent nonspecific post‑Lyme symptoms lacking objective evidence of active infection is not supported. Randomized trials and cohort data show no sustained benefit and document meaningful risks and adverse events from extended antibiotic courses.

Prolonged antibiotic re-treatment (beyond recommended courses) for persistent, unexplained symptoms attributed to prior Lyme disease has not demonstrated consistent benefit in randomized controlled trials. Multiple high-quality trials and reviews found no durable improvement with extended antibiotic retreatment and highlighted significant treatment-related harms.

Use of investigational diagnostic tests — including SPECT, PET, iSpot/ELISPOT and modified interferon‑gamma assays, lymphocyte proliferation assays, and other experimental immune- or biomarker-based tests — lacks sufficient evidence for routine diagnostic use. Available studies report variable performance and are not adequate to support these tests as standard diagnostic modalities for Lyme disease.

Prolonged courses of IV antibiotics (extended re‑treatment) for persistent post‑treatment Lyme symptoms have not shown consistent benefit in randomized trials and may be associated with severe adverse events. The evidence does not support routine extended IV antibiotic retreatment for post‑treatment symptoms.

Alternative nonpharmacologic or unconventional therapies (for example, oxygen/reactive-oxygen therapy, energy- and radiation-based therapies, and other listed interventions) have not demonstrated benefit for chronic Lyme-related symptoms in available reports and, in some settings, have been harmful; these approaches are not supported as standard treatment.

Coding Guidance and Applicable Codes

CPT codes covered if selection criteria are metCPTCovered

0041U	Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM.
0042U	Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG.
0043U	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM.
0044U	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG.
84181	Western Blot, with interpretation and report, blood or other body fluid.
84182	Western Blot, with interpretation and report, blood or other body fluid, immunological probe for band identification, each.
86617	Borrelia burgdorferi (Lyme disease) confirmatory test (e.g., Western Blot or immunoblot).
86618	Borrelia burgdorferi (Lyme disease).
88346	Immunofluorescence, per specimen; initial single antibody stain procedure.
88350	Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).

1–10 of 19

1/2

CPT codes not covered / other not-covered tests and servicesmixedNot Covered

0232T	Injection(s), platelet rich plasma, any site.
0316U	Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine.
77401-77417	Radiation treatment delivery (not covered).
78608-78609	Brain imaging, PET; metabolic or perfusion evaluation (not covered).
78811-78816	Positron emission tomography (PET) (not covered).
82136	Amino acids, 2 to 5 amino acids, quantitative (not covered).
82533	Cortisol; total (not covered).
82626	Dehydroepiandrosterone (DHEA) (not covered).
83088	Histamine (not covered).
83497	Hydroxyindolacetic acid, 5-(HIAA) (not covered).

1–10 of 32

1/4

HCPCS codes covered if selection criteria are metHCPCSCovered

G0068	Professional services for the administration of anti-infective, pain management, chelation, pulmonary hypertension, and/or inotropic infusion drug(s) for each infusion drug administration calendar day in the individual's home, each 15 minutes.
S9494-S9504	Home infusion therapy, antibiotic, antiviral, or antifungal therapy.

ICD-10 codes covered / not coveredICD-10

A69.20-A69.29	Lyme disease (covered if selection criteria are met).
A28.1	Cat-scratch disease (not covered).
A44.0-A44.9	Bartonellosis (not covered).
A78	Q fever (not covered).
B60.0	Babesiosis (not covered).
G51.0	Bell's palsy (not covered).
R53.82	Chronic fatigue, unspecified (not covered).
Z11.2	Encounter for screening for other bacterial diseases (testing ticks not covered).
Z11.8	Encounter for screening for other infectious and parasitic diseases (testing ticks not covered).

inv-26: Laboratory recency for repeat IV therapy

RequirementLaboratory results must have been obtained within the past 3 months to qualify for a repeat outpatient 4-week IV antibiotic course.

ContextApplies when member met criteria for an initial IV antibiotic course and completed that initial course.

LimitPolicy allows one repeat 4-week course when criteria (including recent labs) are met.

inv-27: PR interval

Threshold>= 300 milliseconds (markedly prolonged PR interval indicating need for inpatient monitoring and IV antibiotics).

Clinical action

Provider Actions, Prior Authorization, and Documentation Requirements

Prior Authorization

Prior authorization for outpatient IV antibiotics/infusion services

Prior authorization is required for outpatient IV antibiotic therapy and home infusion services. Outpatient IV antibiotic therapy is covered only when selection criteria for a definitive diagnosis of Lyme disease are documented and medical-necessity criteria for initial or repeat IV therapy are met (see diagnostic documentation and medical necessity criteria).

Affected services: outpatient IV antibiotic infusion administration and home infusion service codes (e.g., CPT 96365–96368 series as applicable).
Prior authorization applies before initiation of outpatient/home IV therapy.

Prior Authorization

IV ceftriaxone for CNS disease or persistent Lyme arthritis

Parenteral ceftriaxone (2 g once daily in adults; weight‑based dosing in children) is the recommended IV agent for patients with central nervous system (CNS) Lyme disease (neuroborreliosis) and for patients with Lyme arthritis who fail an appropriate course of oral therapy. Documentation must show indication (CNS disease or oral-treatment failure) and prior authorization when outpatient IV therapy is requested.

IV ceftriaxone dosing: 2 g IV daily in adults; pediatric dosing 50–75 mg/kg IV once daily as clinically indicated.

Background and Evidence Summary

The appropriate use and duration of IV antibiotics for Lyme disease is controversial. Evidence from randomized trials and cohort studies supports short, guideline-recommended courses for specific indications (for example, oral doxycycline for erythema migrans and IV ceftriaxone 2 g/day for neurologic or severe disease). Randomized trials of prolonged IV antibiotic regimens for persistent symptoms have not demonstrated sustained benefit and have identified important treatment-related risks, underscoring the need to reserve IV therapy for established indications with objective evidence of organ involvement.

Definitions and Diagnostic Criteria

inv-54: Positive Western Blot criteria (CDC-adapted)

IgM criteriaIgM immunoblot: presence of 2 of the following bands — 21/22/23/24 kDa (OspC), 39 kDa (BmpA), 41 kDa (Fla).

IgG criteriaIgG immunoblot: presence of 5 of the following bands — 18 kDa; 21/22/23/24 kDa (OspC); 28 kDa; 30 kDa; 39 kDa (BmpA); 41 kDa (Fla); 45 kDa; 58 kDa; 66 kDa; 93 kDa.

Two-step recommendationWestern blot is used to confirm a positive or equivocal EIA/ELISA or IFA per CDC two-test approach.

inv-55: Post‑Lyme disease (PLD) / Post‑Lyme disease syndrome (PLDS)

DefinitionPersistent symptoms (musculoskeletal pain, fatigue, neurocognitive complaints) after prior treatment for Lyme disease; when symptoms persist >6 months often termed PLDS.

Clinical implication

Policy Summary

PayerAetna

PolicyLyme Disease and other Tick-Borne Diseases

Policy CodePolicy 0215

Change TypeNo material change

Effective DateMar 17, 1998

Next Review DateFeb 22, 2024

Key ActionObtain objective clinical signs and validated serology/CSF testing before authorizing outpatient IV antibiotic therapy.

SourceLink

On This Page

Erythema migrans: Oral doxycycline 200 mg once daily for 10 days (evidence supports 10-day courses); alternatives include amoxicillin, cefuroxime, or azithromycin; children <8 years: amoxicillin.erythema migrans diagnosis

Multiple ambulatory trials support short-course oral therapy

Lyme arthritis: First-line: oral doxycycline (200 mg daily or 100 mg twice daily) for 30 days; amoxicillin is an alternative. Persistent or recurrent joint swelling after a recommended oral course: IV ceftriaxone 2 g daily for 14–21 days. Positive synovial fluid PCR increases diagnostic certainty.persistent joint swelling after oral therapy

Gaubitz summary

~90 days total evaluated

Klempner trials and others

Hospitalize and monitor with telemetry if PR >= 300 ms; continue IV antibiotics until PR < 300 ms and high-grade AV block resolves.

Therapy transitionOnce PR < 300 ms, switch to oral therapy to complete a 21–28 day course.

Indications: CNS manifestations (e.g., encephalitis, confirmed meningitis with CSF evidence) or persistent Lyme arthritis after adequate oral therapy.

Prior Authorization

IV therapy for cardiac indications

IV antibiotic therapy is recommended for hospitalized patients with symptomatic Lyme carditis with high‑grade atrioventricular block or marked PR prolongation. When IV therapy is required, ceftriaxone (2 g IV once daily in adults) is the preferred agent; continue IV therapy until high‑grade AV block resolves and PR interval is < 300 ms, then switch to oral therapy to complete total recommended duration.

Indications for IV: syncope, dyspnea, chest pain, second- or third-degree AV block, or first-degree AV block with markedly prolonged PR interval (≥300 ms).
Transition: after resolution of high-grade block/PR <300 ms, switch to oral antibiotics (doxycycline, amoxicillin, or cefuroxime) to complete 21–28 day course.

Note

IV vs oral antibiotic therapy

Oral antibiotic therapy is preferred over IV in most circumstances because oral regimens have equivalent efficacy, better tolerability, and lower cost. IV therapy is reserved for specific indications (e.g., hospitalized patients, CNS involvement, severe carditis, or failure of oral therapy).

Oral doxycycline (200 mg daily) is effective for erythema migrans and for many cases of early neurologic Lyme disease in ambulatory patients.
Reserve IV therapy for parenchymal CNS disease, severe neurologic symptoms, hospitalized patients, or oral-treatment failures.

Note

Prior authorization not specified in this section

This section does not specify exact prior authorization code lists or detailed procedural steps for obtaining authorization. Providers should follow the payer's standard prior authorization submission process and include the required clinical documentation described below.

Prior authorization requirement is noted, but check payer portal or contact for current code list and submission instructions.

Denial Risk

IV antibiotic therapy is experimental/investigational for certain indications

IV antibiotic therapy is considered experimental and investigational (and therefore not covered) for certain indications where benefit has not been established, including early Lyme disease, new-onset Lyme arthritis, nonspecific flu‑like syndromes, chronic fatigue syndromes, and asymptomatic persons with only positive serology.

Examples of non-covered/experimental IV indications: early localized Lyme disease, isolated Bell's palsy without other evidence of dissemination, prophylaxis for asymptomatic persons with only positive immunologic tests, mild cardiac involvement (e.g., PR <0.4 s without heart failure), and persistent nonspecific symptoms attributed to Lyme disease (post‑treatment syndromes).

Denial Risk

Risk of denial for inappropriate testing or prolonged antibiotic therapy

Requests for testing or prolonged antibiotic therapy may be denied when the pretest probability is low, when testing or treatment is not supported by objective findings, or when prolonged/repeated antibiotic courses lack evidence of sustained benefit and carry known risks.

Risk factors for denial: ordering serologic tests for nonspecific symptoms without objective signs, initiating antibiotics based solely on positive serology without compatible clinical findings, and requesting repeated/prolonged IV antibiotics for post‑treatment symptoms without objective evidence of ongoing infection.

Denial Risk

Requests for long-term or combined antibiotics

Requests for long‑term or combined antibiotic regimens for Lyme disease are not supported by evidence and are generally not recommended; documentation must justify any deviation from standard recommended durations and single‑agent therapy.

There is no evidence to recommend long‑term (> standard course) or combined antibiotic treatments for Lyme arthritis or other Lyme manifestations.
Combined antibiotics are not mentioned as a therapeutic option in major reviews and guidelines.

Denial Risk

Requests for prolonged antibiotic therapy

Re‑treatment or prolonged antibiotic courses for persistent symptoms attributed to Lyme disease (post‑treatment Lyme syndromes) have not demonstrated sustained benefit in randomized trials and are associated with adverse events; such requests are likely to be denied without objective evidence of relapse or new organ involvement.

Evidence: randomized trials show no durable benefit for prolonged IV antibiotics in post‑Lyme fatigue or encephalopathy and note higher adverse event rates.
A single repeat 4‑week IV course may be considered only when strict criteria for relapse or progression are met and prior documentation is provided.

Note

Clinical Policy Bulletins constitute only a partial, general description of plan benefits

Clinical Policy Bulletins are developed to assist in administering plan benefits and constitute only a partial, general description of plan benefits; they do not constitute a contract and are not medical advice. Treating providers are solely responsible for medical advice and treatment of members.

This bulletin may be updated and is subject to change.
Participating providers are independent contractors; Aetna does not provide health care services or guarantee outcomes.

Documentation Required

Required diagnostic documentation for Lyme disease and neuroborreliosis

Required diagnostic documentation for Lyme disease and neuroborreliosis must include objective signs and validated laboratory support. For neuroborreliosis, document CSF findings consistent with intrathecal antibody production or other confirmatory CSF evidence.

Lyme disease diagnosis: objective signs (erythema migrans or late manifestation) plus serologic testing (EIA/IFA followed by Western blot with CDC criteria).
Neuroborreliosis: CSF pleocytosis and evidence of intrathecal Borrelia antibody production (CSF-to-serum antibody ratio >1.0) or other supportive CSF findings.

Documentation Required

Diagnostic documentation

Diagnostic confirmation should correlate laboratory results with clinical presentation. Positive ELISA should be followed by IgG immunoblot; PCR positivity from synovial fluid adds diagnostic certainty for Lyme arthritis. Positive serology alone does not justify antibiotic therapy without compatible signs/symptoms.

Follow CDC two‑step testing (sensitive EIA/IFA then Western blot); interpret IgM results cautiously beyond 1 month's duration.
Synovial fluid PCR and positive ELISA + IgG immunoblot increase diagnostic certainty for Lyme arthritis.

Documentation Required

Clinical correlation for novel diagnostics

When using novel or nonstandard diagnostics, include clinical correlation and confirmatory testing. Some tests (e.g., urine OspA, antigen capture assays, nonstandard serology interpretations) are not recommended by CDC/IDSA and should be interpreted with caution and accompanied by standard validated tests and clinical findings.

CDC does not recommend urine antigen capture assays; IDSA advises avoiding certain commercially available nonstandard tests lacking validation (e.g., urine antigen, nonstandard serology interpretation, lymphocyte transformation test, CD57 assays).
Provide clinical context (objective signs, symptom timing) when novel tests are submitted for review.

Note

Treating providers are responsible for medical advice and treatment

Treating providers are responsible for medical advice and treatment. The policy provides guidance for coverage determinations but does not replace clinical judgment.

Providers must supply complete clinical documentation to support medical necessity and prior authorization requests.
Aetna is not responsible for clinical care decisions; participating providers are independent contractors.

Step Therapy

Step from oral doxycycline to IV ceftriaxone

Switching from oral doxycycline to IV ceftriaxone is appropriate when patients with Lyme disease fail to respond to an adequate oral course or when clinical severity mandates parenteral therapy (e.g., CNS parenchymal disease, severe carditis). Oral doxycycline (200 mg daily) is effective for many ambulatory early neurologic cases; IV ceftriaxone is indicated for treatment failures or more severe disease.

Oral doxycycline dosing: 200 mg once daily (or 100 mg twice daily) for erythema migrans and many early neurologic cases.
IV ceftriaxone indicated for failure of oral therapy, parenchymal CNS involvement, or other severe manifestations.

Step Therapy

Oral-before-IV preference

Guideline preference is oral-before-IV: oral therapy is effective and preferred in most circumstances. Step‑therapy principles favor initiating oral antibiotics for appropriate presentations before escalating to IV, except when IV is clearly indicated (hospitalized patients, severe neurologic or cardiac disease).

Oral-before-IV preference is supported by guidelines emphasizing equivalent efficacy of oral regimens for many presentations and reserving IV for specific indications.
When documentation shows a clear indication for immediate IV therapy (e.g., high‑grade AV block, CNS parenchymal disease), prior authorization should cite the indication.

Step Therapy

Step therapy preference for oral antibiotics / No step therapy requirements are provided

While guideline-based step‑therapy preference favors oral regimens first, this policy does not establish a formal administrative step‑therapy program with mandated prior authorization sequences beyond standard prior authorization requirements; clinical exceptions apply when IV therapy is immediately indicated.

No formal step‑therapy administrative requirements are specified in this section; follow standard prior authorization processes and document clinical rationale for IV initiation when applicable.

Positive serology alone is not sufficient; symptoms must be correlated with laboratory confirmation and clinical findings.

Antibiotic responseAntibiotic therapy has not been shown to impact PLDS (no proven benefit for prolonged/repeated antibiotics).

inv-56: Lyme neuroborreliosis (LNB) — definition

DefinitionCNS invasion by Borrelia burgdorferi supported by compatible neurologic symptoms, CSF lymphocytic pleocytosis, and evidence of intrathecal Borrelia-specific antibody production (CSF:serum antibody ratio > 1.0).

Supporting CSF findingsMild mononuclear pleocytosis and elevated protein may be present; intrathecal antibody production is the most helpful CSF test.

Diagnostic testingPaired CSF and serum samples distinguish intrathecal production from serum leakage; positive test documents CNS invasion with rare exceptions.

inv-57: Lyme neuroborreliosis (LNB) — alternate note re acute LNB <6 months

Acute LNB timeframeAcute LNB typically defined by symptom duration less than 6 months.

Treatment noteOral doxycycline and IV ceftriaxone are equally effective for peripheral nervous system disease (including meningitis); CNS manifestations are treated with IV ceftriaxone.

ChildrenChildren treated as adults except doxycycline is contraindicated under age 8 (9 in some countries).

inv-58: Post-treatment Lyme disease syndrome (PTLDS) / PLDS — persistent symptoms >6 months; antibiotics not shown to help

DefinitionPersistent symptoms >6 months after standard treatment are often termed post-treatment Lyme disease syndrome (PTLDS) or PLDS.

Evidence on antibioticsAntibiotic therapy has not been shown to impact PLDS; randomized trials of prolonged antibiotic treatment did not demonstrate additional benefit.

Policy implicationRepeated or prolonged antibiotic courses for PLDS are not supported and may be denied due to lack of evidence and potential harms.

inv-59: Antibiotic-refractory Lyme arthritis (A-RLA)

DefinitionAntibiotic‑refractory Lyme arthritis (A‑RLA) describes persistent Lyme arthritis that does not resolve after recommended antibiotic therapy.

BiomarkersSystematic review identified multiple biomarkers (cytokines, chemokines, immune-cell markers, miRNAs) that differ in A‑RLA versus antibiotic‑responsive Lyme arthritis, but evidence is limited.

Clinical relevancePromising biomarkers (e.g., Th17 cytokines, specific miRNAs) require well‑powered studies before clinical use for predicting A‑RLA.

inv-60: Urinary OspA test (Nanotrap / Galaxy Diagnostics Lyme Borrelia Nanotrap Antigen Test)

Test descriptionUrinary OspA assay (Nanotrap/Galaxy Diagnostics) concentrates OspA C‑terminal peptides from urine using Nanotrap particles and a specific monoclonal antibody for detection.

Reported performanceStudy reported sensitivity down to 1.7 pg/mL; pre-treatment 24/24 newly diagnosed EM patients were urinary OspA positive and 0/117 asymptomatic controls were false positive.

Regulatory/CDC stanceCDC does not recommend urine antigen capture assays for clinical use; urinary OspA testing is investigational and not part of the CDC two-step serology.

inv-61: CDC two-step testing

AlgorithmCDC two-step testing: perform a sensitive ELISA or IFA followed by a standardized Western blot for all specimens that are positive or equivocal on the first test; overall result positive only when both steps are positive.

ImplicationIf the first step is negative, no further testing is recommended; Western blot confirms positive/equivocal first-step results.

Policy notePolicy follows CDC two-test approach; positive serology must be correlated with clinical timing and symptoms before justifying therapy.